

Chammas & Marcheteau advises Bpifrance, Angelor and UI Investissement in the financing round of Dillico (Biotech)

Chammas & Marcheteau advised Bpifrance, Angelor and UI Investissement in Dillico's seed fundraising, alongside GP Compas and Deepbright One funds, as well as private investors and family offices, including its historical investor Deeperly. This capital increase completes a France 2030's non-dilutive financing and new bank financing. These contributions represent a total of €7.5 million.

Founded in 2022, Dillico is a French biotechnology company developing a breakthrough solution for the production of mRNA-based vaccines and therapies. Thanks to its modular and standardized process, Dillico enables faster, more flexible and more economical production, meeting the current challenges of health sovereignty and responsiveness to pandemics.

This funding will enable Dillico to accelerate its development by launching the commercialization of its innovative equipment.

The **Chammas & Marcheteau** team consisted of **Stéphanie Bréjaud** (partner), **Jeanne Cormerais** and **Vincent Lopez** (associates) on corporate aspects, of **Christophe Moreau** (partner) and **Hugo Latrabe** (associate) on tax aspects, of **Coline Bied-Charreton** (partner) and **Floriane Maginot** (associate) on social aspects.

About Chammas & Marcheteau

Chammas & Marcheteau is a Paris-based independent law firm that advises companies, investment funds and entrepreneurs on their transactions and development strategies in France and abroad. With more than 60 specialists in business law, including 16 partners, the Firm offers its clients expertise in Private Equity, Mergers & Acquisitions, Funds and Financial Services, Corporate, Restructuring and Turnaround, Tax, Intellectual Property and Information Technology, Employment Law, Real Estate and Business Litigation.